RxDoctor Payments DataLook up a doctor →

Steven Bettag, MD

Medical Oncology · Sheboygan, WINPI 1669529608

Payments from drug & device makers

$8,045in general payments, 2019–2025

Across 198 payments — averaging $40.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tosoh Bioscience, Inc.$3K
  • Novartis$330
  • E.r. Squibb & Sons, L.L.C.$279
  • Astellas Pharma US Inc$250
  • Genentech USA, Inc.$233
  • Johnson & Johnson$206
  • plus $3K from 53 others

What the payments were for

  • Food & beverage$4,01751%
  • Education$5197%
  • Gifts$3,36843%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,045 in reported general payments places this provider in the 50th percentile of 54 medical oncology providers in Wisconsin.

See all medical oncology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$4,471,887
Medicare patients
351
Services billed
250,969

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide49$812,526
PomalystPomalidomide33$371,427
TagrissoOsimertinib Mesylate14$235,706
VenclextaVenetoclax25$174,849
Abiraterone Acetate43$134,184
AbrysvoRsv Vacc, Pref A And Pref B/Pf250$81,376
Imatinib Mesylate23$43,334
EliquisApixaban56$42,696
ZelborafVemurafenib14$39,567
XareltoRivaroxaban21$17,716
ShingrixVaricella-Zoster Ge/As01b/Pf47$9,862
Tamoxifen Citrate139$4,122
Boostrix TdapDiphth,pertuss(Acell),tet Vac38$2,488
Dexamethasone60$990
Acyclovir48$786

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$134$812,52649 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$279$371,42733 claims
AstraZenecaTagrisso$159$235,70614 claims
AbbVieVenclexta$142$174,84925 claims
PfizerAbrysvo, Eliquis$125$124,073306 claims
Johnson & JohnsonXarelto$206$17,71621 claims
GSKShingrix$15$9,86247 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$24$22742 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 54 medical oncology providers in Wisconsin.

Other medical oncology in Sheboygan

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →